A patent has been filed by Therapeutic Solutions International on its novel cell therapy combination for enhancing lung repair in the COVID-19 model.
- ByManjeet Singh | September 27, 2021
On September 22, Therapeutic Solutions International announced that it had filed a patent demonstrating synergistic suppression of lung injury and acceleration of lung regeneration by combining T regulatory cells and JadiCells.
Researchers have observed synergistic suppression of lung damage when umbilical cord blood T regulatory cells are administered together with JadiCells in endotoxin and poly(IC) models. In addition, blocking TNF receptor GITR resulted in suppressing synergy, suggesting a molecular mechanism.
Dr. James Veltmeyer, Chief Medical Officer of the Company, says, “Science does not stop and can never stop. Therefore, we are always seeking to improve the efficacy of our therapies and understand molecular mechanisms behind them.” “The current discovery provides for novel means of suppressing lung damage, as well as preventing long term-scarring which is a major issue in certain COVID-19 patients.”
As a result of COVID-19, the lungs possess scarring that causes breathing difficulties. Scarring in functional lung areas can be quantified to lead to lung damage. for as long
Follow Startup Story
Related Posts
